Vincenzo Dadduzio - Concepedia

Author

Vincenzo Dadduzio

Istituti di Ricovero e Cura a Carattere Scientifico ORCID

Also Known As

V Dadduzio, V. Dadduzio, V., Dadduzio, Vincenzo Dadduzio

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico Istituto Oncologico Veneto University of Padua University of Bologna Humanitas University

About

Vincenzo Dadduzio is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	448
2	Hepatology	7	7	238
3	Health Sciences	6	6	220
4	Epidemiology	1	1	13
5	Geriatrics	1	1	17

Vincenzo Dadduzio

Publications

861

Citations

H-Index

Page 1

	Year	Citations
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, Journal of Clinical Oncology PathologyPrior SorafenibPharmacotherapyOncologyHepatobiliary Tumor	2018	97
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, Clinical Cancer Research	2020	82
Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center Camillo Aliberti, Riccardo Carandina, Sara Lonardi, Journal of Vascular and Interventional Radiology Surgical OncologySmall Drug-eluting BeadsHepatologyMedicineTransarterial Chemoembolization	2017	51
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, Clinical Colorectal Cancer OncologyAcquired ResistanceMedicineColorectal CancerPathology	2019	51
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Liver Cancer	2021	48
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib Vincenzo Dadduzio, Francesco Tovoli, Giulia Bertolini, PLoS ONE	2020	47
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study Giovanni Schinzari, Ernesto Rossi, Alessandra Cassano, Melanoma Research First Line ChemotherapyTumor ShrinkageMedicineMelanomaPharmacology	2017	42
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer Fotios Loupakis, Paola Biason, Alessandra Anna Prete, British Journal of Cancer	2019	31
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2 Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Liver International	2020	31
Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer Mitsukuni Suenaga, Marta Schirripa, Shu Cao, European Journal of Cancer MedicinePathologyColorectal CancerPotential RoleCancer Genomics	2017	30

Page 1